Effect of Low-Concentration Atropine Eye Drops in Controlling the Progression of Myopia in Children: A One- and Two-Year Follow-Up Study

References

• Baird PN, Saw SM, Lanca C, et al. Myopia. Nat Rev Dis Primers. 2020;6(1):99. doi: 10.1038/s41572-020-00231-4
   PubMed Web of Science ®Google Scholar
• Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high Myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036–1042. doi: 10.1016/j.ophtha.2016.01.006
   PubMed Web of Science ®Google Scholar
• Resnikoff S, Jonas JB, Friedman D, et al. Myopia - a 21st century public health issue. Invest Ophthalmol Vis Sci. 2019;60(3):Mi–Mii. doi: 10.1167/iovs.18-25983
   PubMed Web of Science ®Google Scholar
• Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128(11):1561–1579. doi: 10.1016/j.ophtha.2021.04.032
   PubMed Web of Science ®Google Scholar
• Zhu QR, Liu LQ. Relationship between myopia and light exposure. Sichuan Da Xue Xue Bao Yi Xue Ban. 2021;52(6):901–906. doi: 10.12182/20211160205
   PubMedGoogle Scholar
• Shinojima A, Negishi K, Tsubota K, Kurihara T. Multiple factors causing myopia and the possible treatments: A mini review. Front Public Health. 2022;10:897600. doi: 10.3389/fpubh.2022.897600
   PubMed Web of Science ®Google Scholar
• Modjtahedi BS, Abbott RL, Fong DS, Lum F, Tan D. Reducing the global burden of myopia by delaying the onset of myopia and reducing myopic progression in children: The Academy’s task force on Myopia. Ophthalmology. 2021;128(6):816–826. doi: 10.1016/j.ophtha.2020.10.040
   PubMed Web of Science ®Google Scholar
• Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923. doi: 10.1016/j.preteyeres.2020.100923
   PubMed Web of Science ®Google Scholar
• Cooper J, Tkatchenko AV. A Review of current concepts of the etiology and treatment of Myopia. Eye Contact Lens. 2018;44(4):231–247. doi: 10.1097/icl.0000000000000499
   PubMed Web of Science ®Google Scholar
• Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3–13. doi: 10.1038/s41433-018-0139-7
   PubMed Web of Science ®Google Scholar
• Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: Aetiology and prevention. Prog Retin Eye Res. 2018;62:134–149. doi: 10.1016/j.preteyeres.2017.09.004
   PubMed Web of Science ®Google Scholar
• Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379(9827):1739–1748. doi: 10.1016/s0140-6736(12)60272-4
   PubMed Web of Science ®Google Scholar
• Ganesan P, Wildsoet CF. Pharmaceutical intervention for myopia control. Expert Rev Ophthalmol. 2010;5(6):759–787. doi: 10.1586/eop.10.67
   PubMedGoogle Scholar
• Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for Myopia control in children: A network meta-analysis. Ophthalmology. 2016;123(4):697–708. doi: 10.1016/j.ophtha.2015.11.010
   PubMed Web of Science ®Google Scholar
• Whatham AR, Lunn D, Judge SJ. Effects of monocular atropinization on refractive error and eye growth in infant new World Monkeys. Invest Ophthalmol Vis Sci. 2019;60(7):2623–2630. doi: 10.1167/iovs.18-24490
   PubMed Web of Science ®Google Scholar
• Yam JC, Jiang Y, Tang SM, et al. Low-concentration atropine for myopia progression (LAMP) Study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in Myopia Control. Ophthalmology. 2019;126(1):113–124. doi: 10.1016/j.ophtha.2018.05.029
   PubMed Web of Science ®Google Scholar
• Rabbetts RB. Bennett And Rabbett’s Clinical Visual Optics. Bennett and Rabbett’s clinical visual optics; 2007.
   Google Scholar
• Medina A. The cause of myopia development and progression: Theory, evidence, and treatment. Surv Ophthalmol. 2022;67(2):488–509. doi: 10.1016/j.survophthal.2021.06.005
   PubMed Web of Science ®Google Scholar
• Jonas JB, Wang YX, Dong L, Guo Y, Panda-Jonas S. Advances in myopia research anatomical findings in highly myopic eyes. Eye Vis (Lond). 2020;7(1):45. doi: 10.1186/s40662-020-00210-6
   PubMedGoogle Scholar
• Lejoyeux R, Benillouche J, Ong J, et al. Choriocapillaris: Fundamentals and advancements. Prog Retin Eye Res. 2022;87:100997. doi: 10.1016/j.preteyeres.2021.100997
   PubMed Web of Science ®Google Scholar
• Yu Q, Zhou JB. Scleral remodeling in myopia development. Int J Ophthalmol. 2022;15(3):510–514. doi: 10.18240/ijo.2022.03.21
   PubMed Web of Science ®Google Scholar
• Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285–2291. doi: 10.1016/j.ophtha.2006.05.062
   PubMed Web of Science ®Google Scholar
• Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347–354. doi: 10.1016/j.ophtha.2011.07.031
   PubMed Web of Science ®Google Scholar
• Yam JC, Li FF, Zhang X, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) Study: phase 2 report. Ophthalmology. 2020;127(7):910–919. doi: 10.1016/j.ophtha.2019.12.011
   PubMed Web of Science ®Google Scholar
• Rudnicka AR, Kapetanakis VV, Wathern AK, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol. 2016;100(7):882–890. doi: 10.1136/bjophthalmol-2015-307724
   PubMed Web of Science ®Google Scholar
• Lee JJ, Fang PC, Yang IH, et al. Prevention of myopia progression with 0.05% atropine solution. J Ocul Pharmacol Ther. 2006;22(1):41–46. doi: 10.1089/jop.2006.22.41
   PubMed Web of Science ®Google Scholar
• Li FF, Zhang Y, Zhang X, et al. Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration atropine for Myopia progression study. Ophthalmology. 2021;128(8):1180–1187. doi: 10.1016/j.ophtha.2020.12.036
   PubMed Web of Science ®Google Scholar
• Mei H, Zhao L, Li W, et al. Inhibition of ferroptosis protects house ear institute-organ of Corti 1 cells and cochlear hair cells from cisplatin-induced ototoxicity. J Cell Mol Med. 2020;24(20):12065–12081. doi: 10.1111/jcmm.15839
   PubMed Web of Science ®Google Scholar
• Li FF, Kam KW, Zhang Y, et al. Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: low-Concentration Atropine for Myopia Progression Study. Ophthalmology. 2020;127(12):1603–1611. doi: 10.1016/j.ophtha.2020.06.004
   PubMed Web of Science ®Google Scholar